Accepted at 9:07 a.m. Dec, 28, 2024 by Eli.Tanenbaum
Author: andrewmathias8
Related Note: 1509211365441
Rationale for change

format + Extra
Source: AMBOSS - https://next.amboss.com/us/article/qM0Cpg?utm_source=navbar&utm_medium=anki&utm_campaign=anki&utm_term=azathioprine&guid=t-J%253C6%253DP1v%252B&aid=298bfc66-b119-4c76-b7ef-8bfc7d192ab2&uid=ptfeLeLy0#Z826df053927ec3e8abd5d55515708e41

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::12_Antimetabolites::*Purine_Synthesis_Inhibitors::Azathioprine #AK_Step1_v12::#Bootcamp::Immunology::13_Transplant_Rejection::07_Immunosuppressants #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::04_Azathioprine/6-MP #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::10_Cell_Cycle_Dependent_Drug_Targets #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::01_Antimetabolites::02_Azathioprine,_6-mercaptopurine,_Mycophenolate_Mofetil #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::08_Principles_of_Oncology_and_Therapeutics::10_Cell_Cycle_Dependent_Drug_Targets #AK_Step1_v12::#Physeo::09_Pharm::01_Immunology::05_Azathioprine_&_6_MP #AK_Step1_v12::#OME::PreClinical::Immunology #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::01_Immunosuppressants::*Azathioprine #AK_Other::#AK_Original_Decks::Step_1::Lolnotacop::Drugs #AK_Step1_v12::#Low/HighYield::3-HighYield-temporary